Pozniak, A., Arribas, J. R., Gathe, J., Gupta, S. K., Post, F. A., Bloch, M., . . . Fordyce, M. W. (2016). Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr.
Citação norma ChicagoPozniak, Anton, et al. "Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study." J Acquir Immune Defic Syndr 2016.
MLA CitationPozniak, Anton, et al. "Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study." J Acquir Immune Defic Syndr 2016.